TOUCHENDOCRINOLOGY

New Research on the Effect of Body Lotions on Capillary Blood Glucose Measurement - Interference of Hydroquinone-containing Body Lotion with Capillary Glucose Measurement - touchENDOCRINOLOGY

Retrieved on: 
Thursday, May 24, 2018
Diabetes, Blood tests, Medicine, Clinical medicine, Endocrine system, Blood glucose monitoring, Blood sugar level, Glucose, Capillary, Glucose meter

The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.

Key Points: 
  • The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.
  • Some factors independent of glucose control could however affect readings during ambulatory monitoring of capillary glucose levels in patients with diabetes mellitus.
  • They observed a significant increase (delta [95% confidence interval, CI]: 119.5% [77.4-222.1]) of capillary glucose level immediately after administration of hydroquinone-containing body lotion (p
  • They observed from our study that there were significant variations in capillary blood glucose measurements induced by the use of hydroquinone lotion.

New Research on the Effect of Body Lotions on Capillary Blood Glucose Measurement - Interference of Hydroquinone-containing Body Lotion with Capillary Glucose Measurement - touchENDOCRINOLOGY

Retrieved on: 
Thursday, May 24, 2018
Diabetes, Blood tests, Medicine, Clinical medicine, Endocrine system, Blood glucose monitoring, Blood sugar level, Glucose, Capillary, Glucose meter

The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.

Key Points: 
  • The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.
  • Some factors independent of glucose control could however affect readings during ambulatory monitoring of capillary glucose levels in patients with diabetes mellitus.
  • They observed a significant increase (delta [95% confidence interval, CI]: 119.5% [77.4-222.1]) of capillary glucose level immediately after administration of hydroquinone-containing body lotion (p
  • They observed from our study that there were significant variations in capillary blood glucose measurements induced by the use of hydroquinone lotion.

New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY

Retrieved on: 
Thursday, May 24, 2018
Glucosides, SGLT2 inhibitors, Business, Solute carrier family, Biotechnology, Health, Anti-diabetic drugs, Gliflozin, Canagliflozin, Empagliflozin, Boehringer Ingelheim, SGLT2

T2D is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions.

Key Points: 
  • T2D is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions.
  • Recently published data from the Canagliflozin Cardiovascular Assessment Study (CANVAS-PROGRAM) study suggested that the cardiovascular benefits of empagliflozin are also seen with the SGLT2-inhibitor canagliflozin, indicating a class effect of SGLT2 inhibitors.
  • Speaker honoraria: Amgen, Abbott, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novo Nordisk, Sanofi.
  • The views and opinions expressed are those of the author and do not necessarily reflect those of AstraZeneca.

New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY

Retrieved on: 
Thursday, May 24, 2018
Glucosides, SGLT2 inhibitors, Business, Solute carrier family, Biotechnology, Health, Anti-diabetic drugs, Gliflozin, Canagliflozin, Empagliflozin, Boehringer Ingelheim, SGLT2

T2D is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions.

Key Points: 
  • T2D is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions.
  • Recently published data from the Canagliflozin Cardiovascular Assessment Study (CANVAS-PROGRAM) study suggested that the cardiovascular benefits of empagliflozin are also seen with the SGLT2-inhibitor canagliflozin, indicating a class effect of SGLT2 inhibitors.
  • Speaker honoraria: Amgen, Abbott, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novo Nordisk, Sanofi.
  • The views and opinions expressed are those of the author and do not necessarily reflect those of AstraZeneca.

touchENDOCRINOLOGY Announce PubMed Central Indexing for European Endocrinology

Retrieved on: 
Tuesday, May 1, 2018
Publishing, Academic publishing, Scholarly communication, PubMed Central, Journal of Molecular Endocrinology

touchENDOCRINOLOGY are pleased to announce that their journal European Endocrinology has been accepted for indexing on PubMed and PubMed Central.

Key Points: 
  • touchENDOCRINOLOGY are pleased to announce that their journal European Endocrinology has been accepted for indexing on PubMed and PubMed Central.
  • The journal's Editor-in-Chief, Abd Tahrani commented "I am delighted that European Endocrinology has received PubMed-indexing, which will increase the exposure of content from this excellent journal".
  • Barney Kent, Group Managing Director at touchENDOCRINOLOGY continued "This is a great step forward for the journal and we are excited to see how European Endocrinology develops over the coming years.
  • European Endocrinology welcomes authors to submit their work here , and author information is available at touchENDOCRINOLOGY.com.

New Review of Flash Continuous Glucose Monitoring and its IMPACT to REPLACE Blood Glucose Monitoring in the Management of Type 1 and Type 2 Diabetes - touchENDOCRINOLOGY

Retrieved on: 
Tuesday, April 24, 2018
Health, Diabetes, Clinical research, Design of experiments, Medicine, Diabetes management, Clinical trial, CGM, Randomized controlled trial, Blood glucose monitoring

Flash CGM is a novel form of self-monitoring that provides on-demand continuous interstitial glucose profiles.

Key Points: 
  • Flash CGM is a novel form of self-monitoring that provides on-demand continuous interstitial glucose profiles.
  • The purpose of this article is to critically review the recent outcome data from randomized controlled trials that assessed the efficacy and safety of flash CGM to replace routine SMBG in diabetes management.
  • Methods: Two recent six-month, prospective, multicenter, randomized controlled trials in type 1 (IMPACT; NCT02232698) and type 2 (REPLACE; NCT02082184) diabetes compared flash CGM with SMBG under otherwise usual care conditions.
  • Moreover, patient satisfaction improved with flash CGM, usage adherence rates were high, and flash CGM was well tolerated.

New Review of Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance - touchENDOCRINOLOGY

Retrieved on: 
Tuesday, April 24, 2018
Chemistry, Dipeptidyl peptidase-4 inhibitors, Organic chemistry, Alcohols, Nitriles, Pyrrolidines, Vildagliptin, Novartis, Tolerability, Gemigliptin

Over the last decade, a vast panorama of evidence on the benefit-risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM).

Key Points: 
  • Over the last decade, a vast panorama of evidence on the benefit-risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM).
  • In this article, we review the cumulative evidence on the safety of vildagliptin from the clinical development programme, as well as reports of rare adverse drug reactions detected during the post-marketing surveillance of the drug.
  • Across clinical studies, the overall safety and tolerability profile of vildagliptin was similar to placebo, and it was supported by real-world data in a broad population of patients with T2DM, making DPP-4 inhibitors, like vildagliptin, a safe option for managing patients with T2DM.
  • Plamen Kozlovski, Pivi M Paldnius, Vikas Modgill and Carmen Serban are employees and shareholders of Novartis Pharma AG.

New Review of the Clinical Characteristics and Blood Glucose Data from Cellnovo System Users Using Data Collected from the Cellnovo Online Platform - touchENDOCRINOLOGY

Retrieved on: 
Tuesday, April 24, 2018
Medicine, Diabetes, Insulin pump, RTT, Diabetes management, Insulin, Upload

While CSII pumps record a number of data parameters such as BG level, carbohydrate intake, activity and insulin delivered, these data are generally 'locked in' and can only be accessed by uploading to a cloud-based system, thus information is not contemporaneous.

Key Points: 
  • While CSII pumps record a number of data parameters such as BG level, carbohydrate intake, activity and insulin delivered, these data are generally 'locked in' and can only be accessed by uploading to a cloud-based system, thus information is not contemporaneous.
  • The Cellnovo Diabetes Management System (Cellnovo, Bridgend, UK) allows data to be transmitted securely and wirelessly in real time to a secure server, which is then retrieved by an online platform, the Cellnovo Online platform, enabling continuous access by the user and by clinicians.
  • In this article, the authors describe a retrospective review of the patient data automatically uploaded to the Cellnovo Online platform.
  • The full peer-reviewed, open-access article is available here:
    Disclosure:Olivia Hautier-Suply, Yasmin Friedmann and Julian Shapley are employees of Cellnovo Ltd.

New Review of Selecting the Appropriate Continuous Glucose Monitoring System – a Practical Approach - touchENDOCRINOLOGY

Retrieved on: 
Tuesday, April 24, 2018
Diabetes, Medicine, Endocrine system, Endocrinology, Continuous glucose monitor, Dexcom, Blood glucose monitoring, CGM

To be published in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Peter Adolfsson et al, discuss two types of continuous glucose monitoring (CGM) systems are currently available for daily diabetes self-management: real-time CGM and intermittently scanned CGM.

Key Points: 
  • To be published in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Peter Adolfsson et al, discuss two types of continuous glucose monitoring (CGM) systems are currently available for daily diabetes self-management: real-time CGM and intermittently scanned CGM.
  • Both approaches provide continuous measurement of glucose concentrations in the interstitial fluid; however, each has its own unique features that can impact their usefulness and acceptability within specific patient groups.
  • This article explores the strengths and limitations of each approach and provides guidance to healthcare professionals in selecting the CGM type that is most appropriate to the individual needs of their patients.
  • Christopher G Parkin has received consulting fees from CeQur, Dexcom, Insulet, Johnson & Johnson, Mannkind, Roche Diabetes Care and Senseonics.